Short Peptides as Inhibitors of Amyloid Aggregation
- PMID: 24653784
- PMCID: PMC3956661
- DOI: 10.2174/1874070701105010039
Short Peptides as Inhibitors of Amyloid Aggregation
Abstract
The misfolding and aggregation of proteins into amyloid has been linked to a variety of age-related diseases. Aggregation of proteins, such as Aβ in Alzheimer's disease and Islet Amyloid Polypeptide (IAPP, amylin) in type 2 diabetes, appears to lead to the formation of toxic assemblies. These assemblies range in size from small oligomers (2-8 proteins) to large fibrils (thousands of proteins). It remains unclear how these amyloidogenic proteins misfold and form toxic species, but growing evidence suggests that inhibiting the aggregation of these proteins could slow, if not prevent altogether, the progression of these diseases. We describe the use of small peptides (<43 amino acids) as inhibitors of amyloid-based aggregation. These peptides, often short complementary segments of the amyloid proteins, can be useful (i) for identifying the aggregation-prone regions of the amyloid proteins (ii) as models for drug discovery and (iii) as potential therapeutic agents themselves.
Keywords: ABeta; Amylin; Amyloid Inhibition; IAPP; Peptide Libraries.
Conflict of interest statement
None declared.
Figures
References
-
- Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507–11. - PubMed
-
- Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333–66. - PubMed
-
- Murphy RM, Kendrick BS. Protein misfolding and aggregation. Biotech Progress. 2007;23:548–52. - PubMed
-
- Alzheimer’s Disease Facts and Figures. Alzheimer’s Association; 2007. Available from: http://www.alz.org/
-
- Type 2 Diabetes Facts and Figures. American Diabetes Association; 2007. Available from: http://www.diabetes.org.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources